Intravenous Immunoglobulin (IVIg) for Refractory and Difficult-to-treat Infections

Ferrara, Giovanni; Zumla, Alimuddin; Maeurer, Markus

doi:10.1016/j.amjmed.2012.01.023

Cited by 34 publications

(18 citation statements)

References 60 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…No data are available regarding LCMV antibody concentrations in available IVIG preparations, but they are presumed to be low, based on the low LCMV seroprevalence in the general population. The mechanism of action has been attributed to interaction with T‐cell function, antigen‐presenting cell maturation/presentation, combined with decreasing inflammation . Reducing immunosuppression dosing also likely plays an important role in treating LCMV infection.…”

Section: Discussionmentioning

confidence: 99%

High clinical suspicion of donor‐derived disease leads to timely recognition and early intervention to treat solid organ transplant‐transmitted lymphocytic choriomeningitis virus

Mathur

Yadav

Ford

et al. 2017

Transplant Infectious Dis

View full text Add to dashboard Cite

Despite careful donor screening, unexpected donor-derived infections continue to occur in organ transplant recipients (OTRs). Lymphocytic choriomeningitis virus (LCMV) is one such transplant-transmitted infection that in previous reports has resulted in a high mortality among the affected OTRs. We report a LCMV case cluster that occurred 3 weeks post-transplant in three OTRs who received allografts from a common organ donor in March 2013. Following confirmation of LCMV infection at Centers for Disease Control and Prevention, immunosuppression was promptly reduced and ribavirin and/or intravenous immunoglobulin therapy were initiated in OTRs. The liver recipient died, but right kidney recipients survived without significant sequelae and left kidney recipient survived acute LCMV infection with residual mental status deficit. Our series highlights how early recognition led to prompt therapeutic intervention, which may have contributed to more favorable outcome in the kidney transplant recipients.

show abstract

Section: Discussionmentioning

confidence: 99%

High clinical suspicion of donor‐derived disease leads to timely recognition and early intervention to treat solid organ transplant‐transmitted lymphocytic choriomeningitis virus

Mathur

Yadav

Ford

et al. 2017

Transplant Infectious Dis

View full text Add to dashboard Cite

show abstract

“…It was a long journey of more than 100 y from the discovery of Igs to the widespread use of polyclonal normal IgG in several human disorders. The benefits of IVIG therapy in PIDs also encouraged its potential application in various infectious diseases, particularly in patients with diminished immunity (93,94). Although clinical trials have confirmed therapeutic utility of IVIG in many autoimmune diseases, such trials are lacking for the majority of them.…”

Section: Discussionmentioning

confidence: 99%

Passive Serum Therapy to Immunomodulation by IVIG: A Fascinating Journey of Antibodies

João

Negi

Kazatchkine

et al. 2018

The Journal of Immunology

View full text Add to dashboard Cite

The immunoregulatory and anti-infective properties of normal circulating polyclonal Abs have been exploited for the therapeutic purposes in the form of IVIG as well as several hyperimmune globulins. Current knowledge on the therapeutic use of normal Igs is based on the discoveries made by several pioneers of the field. In this paper, we review the evolution of IVIG over the years. More importantly, the process started as an s.c. replacement in γ globulin-deficient patients, underwent metamorphosis into i.m. Ig, was followed by IVIG, and is now back to s.c. forms. Following successful use of IVIG in immune thrombocytopenic purpura, there has been an explosion in the therapeutic applications of IVIG in diverse autoimmune and inflammatory conditions. In addition to clinically approved pathological conditions, IVIG has been used as an off-label drug in more than 100 different indications. The current worldwide consumption of IVIG is over 100 tons per year.

show abstract

“…Apart from well-known microbial antigen-specific binding effects, IVIg is supposed to convert a pro-inflammatory trigger into an anti-inflammatory condition by neutralization of endogenous inflammatory chemokines and cytokines and apoptosis-inducing molecules via naturally occurring autoreactive antibodies [32][33][34] .…”

Section: Fab-mediated Modes Of Actionmentioning

confidence: 99%

Intravenous immunoglobulins in liver transplant patients: Perspectives of clinical immune modulation

Kornberg¹

2015

WJH

View full text Add to dashboard Cite

show abstract

Intravenous Immunoglobulin (IVIg) for Refractory and Difficult-to-treat Infections

Cited by 34 publications

References 60 publications

High clinical suspicion of donor‐derived disease leads to timely recognition and early intervention to treat solid organ transplant‐transmitted lymphocytic choriomeningitis virus

High clinical suspicion of donor‐derived disease leads to timely recognition and early intervention to treat solid organ transplant‐transmitted lymphocytic choriomeningitis virus

Passive Serum Therapy to Immunomodulation by IVIG: A Fascinating Journey of Antibodies

Intravenous immunoglobulins in liver transplant patients: Perspectives of clinical immune modulation

Contact Info

Product

Resources

About